Is Cymbalta a SSRI?
No, Cymbalta (duloxetine) is not a selective serotonin reuptake inhibitor (SSRI)—it is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake of both serotonin and norepinephrine. 1
Pharmacological Classification
- Duloxetine is classified as an SNRI, which is a distinct class from SSRIs 2, 3
- The FDA drug label explicitly states that duloxetine is "a potent inhibitor of neuronal serotonin and norepinephrine reuptake" with approximately 10-fold selectivity for serotonin over norepinephrine 1, 4
- This dual mechanism differentiates SNRIs from SSRIs, which selectively target only serotonin reuptake 5
Key Mechanistic Differences
- SSRIs (such as fluoxetine, sertraline, paroxetine, citalopram, escitalopram) act specifically on synaptic serotonin concentrations by blocking its reuptake in the presynapse 6
- Duloxetine (SNRI) blocks reuptake of both neurotransmitters, with actions believed to be related to potentiation of both serotonergic and noradrenergic activity in the CNS 1
- The norepinephrine reuptake inhibition component is the primary mechanism for controlling visceral pain, which explains duloxetine's efficacy in pain conditions where SSRIs are generally ineffective 7
Clinical Implications of the Distinction
- SNRIs like duloxetine have slightly higher discontinuation rates due to adverse effects compared to SSRIs as a class (67% increased risk for duloxetine versus SSRIs) 8
- Duloxetine demonstrates efficacy in chronic pain conditions (diabetic neuropathy, fibromyalgia, osteoarthritis) where SSRIs are generally ineffective 7, 5
- The dual mechanism produces a different adverse effect profile: at higher doses, duloxetine can cause norepinephrine-related effects such as blood pressure elevation, diaphoresis, tachycardia, and tremors—effects not typically seen with SSRIs 4
Other SNRIs in the Same Class
- The SNRI class includes venlafaxine, desvenlafaxine, duloxetine, milnacipran, and levomilnacipran 9, 10, 4
- Duloxetine is distinguished within the SNRI class by being the only SNRI with FDA approval for generalized anxiety disorder in pediatric patients ≥7 years old 3
Common Clinical Pitfall
Do not confuse duloxetine with SSRIs when counseling patients about expected effects and side effects. The norepinephrine component means duloxetine may cause cardiovascular effects (blood pressure elevation, tachycardia) and has superior efficacy for pain conditions, neither of which applies to SSRIs 8, 7, 4.